Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) granted a stock option inducement award to new Chief Commercial Officer Mark Sims under Nasdaq Listing Rule 5635(c)(4). The award covers 285,000 shares at an exercise price of $10.03, matching the July 6, 2026 Nasdaq closing price.

Options vest 25% after one year from his start date and 75% in 36 equal monthly installments, subject to continued service. The grant was made under Candel’s 2025 Inducement Plan, adopted by the board on December 24, 2025.

News Market Reaction – CADL

+0.10%

+0.10% News Effect

On the day this news was published, CADL gained 0.10%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The grant of 285,000 stock options to the new Chief Commercial Officer formalized his hiring incenti...

Analysis

The grant of 285,000 stock options to the new Chief Commercial Officer formalized his hiring incentives under the 2025 Inducement Plan. Investors may weigh added leadership depth against dilution risk, alongside an active S-3 shelf and elevated short interest.

Key Figures

Inducement options granted: 285,000 shares Exercise price: $10.03 per share Initial vesting tranche: 25% of shares +5 more

8 metrics

Inducement options granted 285,000 shares Stock options for new Chief Commercial Officer

Exercise price $10.03 per share Equal to Nasdaq close on July 6, 2026

Initial vesting tranche 25% of shares Vests on first anniversary of start date

Remaining vesting 75% of shares Vests in 36 equal monthly installments thereafter

Monthly vesting installments 36 months Post‑year one vesting schedule

Inducement plan year 2025 2025 Inducement Plan governing the grant

Grant date July 6, 2026 Date options were approved by Compensation Committee

Plan adoption date December 24, 2025 Board adoption of 2025 Inducement Plan

Historical Context

5 past events · Latest: Jul 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 01	Inducement option grant	Neutral	-0.5%	Nasdaq Rule 5635(c)(4) inducement option for one new employee.
Jun 30	Phase 3 trial initiation	Positive	-0.6%	Launch of global pivotal Phase 3 AURORA trial in metastatic NSCLC.
Jun 25	Leadership appointment	Positive	+2.2%	Appointment of Mark Sims as Chief Commercial Officer for CAN-2409.
Jun 02	Phase 3 clinical data	Positive	-1.1%	Pivotal Phase 3 data showing improved disease-free survival in prostate cancer.
Jun 01	Inducement option grants	Neutral	-1.1%	Inducement stock options for three new employees under 2025 plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, including positive clinical milestones, has often been followed by modestly negative or muted next-day price moves.

Key Terms

nasdaq listing rule 5635(c)(4), inducement stock options, exercise price, vesting

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"The above-described award was granted as inducement material to Mr. Sims entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock options financial

"the Compensation Committee of Candel’s Board of Directors granted Mark Sims ... inducement stock options"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

exercise price financial

"stock options to purchase an aggregate of 285,000 shares ... with a per share exercise price of $10.03"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 6, 2026, the Compensation Committee of Candel’s Board of Directors granted Mark Sims, in connection with his employment as the Chief Commercial Officer of Candel, stock options to purchase an aggregate of 285,000 shares of the Company’s common stock, with a per share exercise price of $10.03, which is equal to the closing price of the Company’s common stock on The Nasdaq Global Market on July 6, 2026.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of Mr. Sims’ start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 36 equal monthly installments thereafter. All vesting related to inducement awards is subject to Mr. Sims’ continuing service at the Company through the applicable vesting date.

The above-described award was granted as inducement material to Mr. Sims entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA) and published in The Lancet Oncology. The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

FAQ

What inducement grant did Candel Therapeutics (CADL) announce on July 8, 2026?

Candel Therapeutics announced stock options to purchase 285,000 shares of common stock for its new Chief Commercial Officer. According to Candel, the options have a $10.03 exercise price and were granted as an employment inducement under Nasdaq Listing Rule 5635(c)(4) and the 2025 Inducement Plan.

What is the exercise price of the Candel Therapeutics (CADL) inducement stock options for Mark Sims?

The exercise price of the inducement stock options is $10.03 per share. According to Candel, this price equals the closing price of its common stock on the Nasdaq Global Market on July 6, 2026, the grant date for the 285,000-share option award.

How do the Candel Therapeutics (CADL) inducement options for Mark Sims vest?

The options vest over four years, with 25% vesting after one year from Mark Sims’ start date. According to Candel, the remaining 75% of the 285,000 options vest in 36 equal monthly installments, contingent on his continued service with the company.

Under which plan were the Candel Therapeutics (CADL) inducement options granted?

The inducement options were granted under Candel’s 2025 Inducement Plan. According to Candel, the board adopted this plan on December 24, 2025, and the July 6, 2026 award to Mark Sims was made pursuant to its terms and Nasdaq Listing Rule 5635(c)(4).

Why did Candel Therapeutics (CADL) use Nasdaq Listing Rule 5635(c)(4) for this stock option grant?

Candel used Nasdaq Listing Rule 5635(c)(4) to grant stock options as a material inducement for Mark Sims to join as Chief Commercial Officer. According to Candel, the 285,000-share award was specifically structured as an employment inducement grant under this rule and the 2025 Inducement Plan.